Insights from 2023 ASH Annual Meeting


 

ASH 2023 Insights: "HARBOR Trial - Elenestinib, an Investigational, Next Gen KIT D816V Inhibitor, in Patients With Indolent Systemic Mastocytosis"

35 views
December 19, 2023
Comments 0
Login to view comments. Click here to Login